Targeting key proximal drivers of type 2 inflammation in disease
The DOI matches its Crossref record; 154 of the 156 references it cites were found in a registry or an index.
Abstract
Systemic type 2 inflammation encompassing T helper 2 (TH2)-type responses is emerging as a unifying feature of both classically defined allergic diseases, such as asthma, and a range of other inflammatory diseases. Rather than reducing inflammation with broad-acting immunosuppressants or narrowly targeting downstream products of the TH2 pathway, such as immunoglobulin E (IgE), efforts to target the key proximal type 2 cytokines - interleukin-4 (IL-4), IL-5 and IL-13 - represent a promising strategy to achieve therapeutic benefit across multiple diseases. After several initial disappointing clinical results with therapies targeting IL-4, IL-5 or IL-13 in asthma, applying a personalized approach achieved therapeutic benefit in an asthma subtype exhibiting an 'allergic' phenotype. More recently, efficacy was extended into a broad population of people with asthma. This argues that the Type 2 inflammation is broadly relevant across the severe asthma population if the key upstream drivers are properly blocked. Moreover, the simultaneous inhibition of IL-4 and IL-13 has shown significant clinical activity in diseases that are often co-morbid with asthma - atopic dermatitis and chronic sinusitis with nasal polyps - supporting the hypothesis that targeting a central 'driver pathway' could benefit multiple allergic diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lebrikizumab does not affect the binding of IL-13 to the IL-13Rα2 receptor chain, the biological role of which remains unclear81.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [81]
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Asher, M. I., Montefort, S., Björkstén, B., Lai, C. K., Strachan, D. P., Weiland, S. K., & Williams, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69283-0 · Cited by 4,223
Interleukin-13: Central Mediator of Allergic Asthma
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., & Donaldson, D. D. (1998) · Science · doi:10.1126/science.282.5397.2258 · Cited by 2,617
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Fokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., Cohen, N., Cervin, A., Douglas, R., Gevaert, P., et al. (2012) · Rhinology journal · doi:10.4193/rhino12.000 · Cited by 2,387
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Research works printed but not linked: 5
- Pawankar, R., Canonica, G., Holgate, S. & Lockey, R. WAO White Book on Allergy 2011–2012: Executive Summary (World Allergy Organization, 2011).
- Wenzel, S. E. et al. Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Eur. Respir. J. 36 (Suppl. 54), 713s (2010).
- Wenzel, S. et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 cells/μl. Am. J. Respir. Crit. Care Med. 191, A3632 (2015).
- Kaiser, J. Medical Officer's Efficacy Review, Genentech, Omalizumab BLA STN 103976/0. US Food and Drug Administration [online] , (2003).
- Groves, R., Wilbrahams, D., Fuller, R. & Longphre, M. Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema. J. Invest. Dermatol. 127 (Suppl. 1s), S54 (2007).
Cited by
Items 301–400 of 800
Staphylococcus aureus in Atopic Dermatitis: Past, Present, and Future
Hwang, J., Jaros, J., & Shi, V. Y. (2020) · Dermatitis · doi:10.1097/der.0000000000000589 · Cited by 18
Chen, L., Xu, J., Chu, X., & Ju, C. (2017) · Bioscience Reports · doi:10.1042/bsr20170149 · Cited by 18
Oliveira, T. D., Ramakrishnan, M., Diamanti, M. A., Ziegler, P. K., Brombacher, F., & Greten, F. R. (2018) · Oncogene · doi:10.1038/s41388-018-0551-2 · Cited by 19
Dupilumab for atopic dermatitis: evidence to date
Rodrigues, M. A., Nogueira, M., & Torres, T. R. (2019) · Giornale Italiano di Dermatologia e Venereologia · doi:10.23736/s0392-0488.19.06417-4 · Cited by 22
Tumor Targeted Delivery of an Anti‐Cancer Therapeutic: An In Vitro and In Vivo Evaluation
Kang, Y. J., Holley, C. K., Abidian, M. R., Madhankumar, A. B., Connor, J. R., & Majd, S. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001261 · Cited by 20
Dupilumab for refractory chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis
Padoan, R., Davanzo, F., Iorio, L., Saccardo, T., Roccuzzo, G., Zampollo, S., Nicolai, P., Doria, A., & Ottaviano, G. (2024) · Rheumatology · doi:10.1093/rheumatology/keae554 · Cited by 17
A review of the current management and burden of prurigo nodularis in the United States
Chisolm, S. S. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89366 · Cited by 20
Chehade, M., Hiremath, G. S., Zevit, N., Oliva, S., Pela, T., Khodzhayev, A., Jacob-Nara, J. A., & Radwan, A. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.08.009 · Cited by 17
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function
Pavord, I. D., Siddiqui, S., Papi, A. A., Corren, J., Sher, L., Bardin, P. G., Langton, D., Park, H., Rice, M. S., Deniz, Y. M., et al. (2020) · Journal of Asthma and Allergy · doi:10.2147/jaa.s275068 · Cited by 19
Self-citationNumazaki, M., Abe, M., Hanaoka, K., Imamura, E., Maeda, M., Kimura, A., Miyanohara, J., Saito, T., Arai, K., Suzuki, H., et al. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000686 · Cited by 20
Wellaway, C. R., Baldwin, I. R., Bamborough, P., Barker, D., Bartholomew, M. A., Chung, C., Dümpelfeld, B., Evans, J. P., Fazakerley, N. J., Homes, P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01765 · Cited by 17
Westermann, S., Dietschmann, A., Döhler, D., Castiglione, K., Bochner, B. S., Voehringer, D., & Radtke, D. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100184 · Cited by 18
Ryser, F. S., Demeter, T., Bergadà-Pijuan, J., Shambat, S. M., Brühlmann, C., Mauthe, T., Hilty, M., Soyka, M., Steiner, U. C., & Brugger, S. D. (2025) · Allergy · doi:10.1111/all.16600 · Cited by 17
Identification of gut microbiota signatures in symptomatic dermographism
Liu, R., Peng, C., Jing, D., Xiao, Y., Zhu, W., Zhao, S., Zhang, J., Li, J., & Chen, X. (2021) · Experimental Dermatology · doi:10.1111/exd.14326 · Cited by 16
Toppila-Salmi, S. K., Bjermer, L. H., Cardell, L., Cervin, A., Heinikari, T., Lehtimäki, L. A., Lundberg, M., Richter, J. C., & Sillanpää, S. (2024) · Journal of Asthma and Allergy · doi:10.2147/jaa.s447093 · Cited by 18
Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP
Bachert, C., Khan, A. H., Fokkens, W. J., Hopkins, C. L., Gevaert, P., Han, J. K., Hellings, P. W., Lee, S. E., Msihid, J., Nash, S., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.07.026 · Cited by 17
Molecular mechanisms of obesity predisposes to atopic dermatitis
Shang, D., & Zhao, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1473105 · Cited by 18
Lane, A. P., Mullol, J., Hopkins, C. L., Fokkens, W. J., Lee, S. E., Msihid, J., Nash, S., Sacks, H. J., Borsos, K., Kamat, S., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2434083 · Cited by 17
García‐Melendo, C., Cubiró, X., & Puig, L. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2020.12.006 · Cited by 19
Effect of dupilumab treatment in a severe asthma patient with EGPA
Matucci, A., Bormioli, S., Bercich, L., Comin, C., Bezzi, M., Vivarelli, E., & Vultaggio, A. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.06.033 · Cited by 16
Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma
Zhang, L., Gao, Y., Li, M., Xu, C. R., Davis, J. D., Kanamaluru, V., & Lü, Q. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12667 · Cited by 16
Chikumoto, A., Oishi, K., Hamada, K., Hirano, T., Kakugawa, T., Kanesada, K., & Matsunaga, K. (2022) · Biomolecules · doi:10.3390/biom12040522 · Cited by 16
Li, G., Gu, L., Zhao, F., Hu, Y., Wang, X., Zeng, F., Yu, J., Yue, C., Zhou, P., Li, Y., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05686-3 · Cited by 16
Dekkers, C., van der Wal, M., van den Noort, L., Bakker, D. S., de Bruin-Weller, M. S., & van Wijk, F. (2023) · Clinical & Experimental Allergy · doi:10.1111/cea.14384 · Cited by 16
Anti-inflammatory Property of Galectin-1 in a Murine Model of Allergic Airway Inflammation
Lv, Y., Dai, M., Wang, M., Chen, F., & Liu, R. (2019) · Journal of Immunology Research · doi:10.1155/2019/9705327 · Cited by 16
Anselmo‐Lima, W. T., Tamashiro, E., Romano, F. R., Miyake, M. M., Roithmann, R., Kosugi, E. M., Nakanishi, M., Fornazieri, M. A., Bezerra, T. F. P., de Mello, J. F., et al. (2021) · Brazilian Journal of Otorhinolaryngology · doi:10.1016/j.bjorl.2021.03.003 · Cited by 20
Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia–Pacific Region
Zhang, Q., Zhong, N. S., Dhooria, S., Fu, X., Fang, H., Lin, J., Zhu, S., Laws, E., Wang, Y., Li, V., et al. (2025) · Clinical & Experimental Allergy · doi:10.1111/cea.70005 · Cited by 16
Mohamed, A. A., Borolossy, R. M. E., Salah, E. M., Hussein, M. S., Muharram, N. M. M., Salawy, N. E., Khalil, M. G., Mahmoud, M. O., Elamir, R. Y., Elsanhory, H. M. A., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1202325 · Cited by 17
RetractedFan, P., Xie, S., Zhang, Z., Yuan, Q., He, J., Zhang, J., Liu, X., Liu, X., & Xu, L. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117288 · Cited by 15
Shih, H.-L., Wang, P.-H., Shih, I., Hu, S., Lin, J., Hsu, P.-Y., & Yang, S. (2023) · International Journal of Food Properties · doi:10.1080/10942912.2023.2292472 · Cited by 16
Mareschal, A., Puzenat, E., & Aubin, F. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3368 · Cited by 15
Andō, K., Tanaka, A., & Sagara, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030889 · Cited by 15
Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity
Garg, D., Que, L. G., & Ingram, J. L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1315540 · Cited by 16
Jin, H., Cai, C., Li, B., Jin, W., Xia, J., Wang, L., & Ma, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00161 · Cited by 15
Silverberg, J. I., Simpson, E. L., Boguniewicz, M., de Bruin-Weller, M. S., Foley, P. A., Kataoka, Y., Bégo-Le-Bagousse, G., Chen, Z., Shumel, B. S., Chao, J., et al. (2021) · Acta Dermato Venereologica · doi:10.2340/actadv.v101.307 · Cited by 16
Sun, X., Liu, K., Zhao, Y., & Zhang, T. (2022) · BMC Molecular and Cell Biology · doi:10.1186/s12860-022-00413-w · Cited by 15
Dendritic cell proliferation by primary cilium in atopic dermatitis
Toriyama, M., Rizaldy, D., Nakamura, M., Atsumi, Y., Toriyama, M., Fujita, F., Okada, F., Morita, A., Itoh, H., & Ishii, K. J. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1149828 · Cited by 15
Post-Translational Modifications in Atopic Dermatitis: Current Research and Clinical Relevance
Ma, X., Ru, Y., Luo, Y., Kuai, L., Chen, Q., Bai, Y. C., Liu, Y., Chen, J., Luo, Y. Y., Song, J., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.942838 · Cited by 14
Greugny, E. T., Bensaci, J., Fages, F., & Stamatas, G. N. (2022) · Experimental Dermatology · doi:10.1111/exd.14698 · Cited by 14
Gu, X., Chen, Y., Qian, P., He, T., Wu, Y., Lin, W., Zheng, J., & Hong, M. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154657 · Cited by 15
Kim, J. H., & Samra, M. S. (2023) · Korean Journal of Pediatrics · doi:10.3345/cep.2022.00346 · Cited by 14
Pavord, I. D., BOURDIN, A. A., Papi, A. A., Domingo, C., Corren, J., Altincatal, A., Radwan, A., Pandit‐Abid, N., Jacob-Nara, J. A., Deniz, Y. M., et al. (2023) · Allergy · doi:10.1111/all.15792 · Cited by 15
Li, Q., Wu, Y., Guo, X., Wang, R., Mao, Y.-H., Zhao, Y., Zou, J., Li, C., Chen, Y., & Yang, Y. (2020) · Inflammation Research · doi:10.1007/s00011-020-01379-1 · Cited by 15
T2-associated diseases: focus on the comorbid patient
Кузубова, Н. А., & Titova, O. N. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-17-57-64 · Cited by 14
Current evaluation and management of patients with chronic rhinosinusitis and nasal polyps
Cantu, J. C. C., Alobid, I., & Mullol, J. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2128767 · Cited by 14
Jeong, G. H., & Lee, J. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417322 · Cited by 15
Rudolph, A.-K., Walter, T., & Erkel, G. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.10.033 · Cited by 14
Contributions of asthma, rhinitis and IgE to exhaled nitric oxide in adolescents
Flashner, B. M., Rifas‐Shiman, S. L., Oken, E., Camargo, C. A., Platts‐Mills, T. A. E., Workman, L. J., Litonjua, A. A., Gold, D. R., & Rice, M. B. (2021) · ERJ Open Research · doi:10.1183/23120541.00945-2020 · Cited by 14
Innate Immune Regulation of Dermatitis
Abreu, D., & Kim, B. (2021) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.04.011 · Cited by 15
Wang, X., Huang, Y., Li, X., He, Y., & Liu, X. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1251827 · Cited by 13
Anselmo‐Lima, W. T., Romano, F. R., Tamashiro, E., Roithmann, R., Dinarte, V. R. P., Piltcher, O. B., Miyake, M. M., Fornazieri, M. A., Nakanishi, M., Bezerra, T. F. P., et al. (2024) · Brazilian Journal of Otorhinolaryngology · doi:10.1016/j.bjorl.2024.101394 · Cited by 18
Kimura’s disease treated with dupilumab: A case report and literature review
Luo, S., Zhou, K., Wang, Q., Deng, L., & Fang, S. C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111895 · Cited by 13
Xue, R., Li, G., Zhou, Y., Wang, B., Xu, Y., Zhao, P., Teng, L., Zheng, J., Liu, H., Ji, S., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.08.033 · Cited by 13
Xu, G., Paglialunga, S., Qian, X., Ding, R., Webster, K., van Haarst, A. D., Engel, C., Hui, C. W., Lam, L. H., Li, W., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1495540 · Cited by 13
Wang, A., Zhou, Y., Luo, Y., Gao, Y., Chen, J., Li, W., Luo, X., & Yao, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160710 · Cited by 14
Potential Aspects of the Use of Cytokines in Atopic Dermatitis
Krupka‐Olek, M., Bożek, A., Aebisher, D., Bartusik‐Aebisher, D., Cieślar, G., & Kawczyk‐Krupka, A. (2024) · Biomedicines · doi:10.3390/biomedicines12040867 · Cited by 13
van der Rijst, L. P., Groot, K. M. D. W., Zuithoff, N. P. A., de Bruin-Weller, M. S., & de Graaf, M. (2024) · Pediatric Allergy and Immunology · doi:10.1111/pai.14178 · Cited by 13
DaSilva‐Arnold, S. C., Thyagarajan‐Sahu, A., Seymour, L. J., Yi, Q., Bradish, J. R., Al‐Hassani, M., Zhou, H., Perdue, N. J., Nemeth, V., Krbanjevic, A., et al. (2018) · Archives of Dermatological Research · doi:10.1007/s00403-018-1807-y · Cited by 14
Khumalo, J., Kirstein, F., Scibiorek, M., Hadebe, S., & Brombacher, F. (2019) · Allergy · doi:10.1111/all.14137 · Cited by 16
A Therapeutic Renaissance - Emerging Treatments for Atopic Dermatitis
Na, C. H., Baghoomian, W., & Simpson, E. L. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3515 · Cited by 13
Wu, S., Wang, L., Cui, B., Wen, X., Jiang, Z., & Hu, S. (2023) · Antioxidants · doi:10.3390/antiox12122049 · Cited by 12
Mast Cells in Autism Spectrum Disorder—The Enigma to Be Solved?
Kovacheva, E., Gevezova, M., Maes, M. H. J., & Sarafian, V. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052651 · Cited by 12
Bhatt, S. P., Rabe, K. F., Hanania, N. A., Vogelmeier, C. F., Bafadhel, M., Christenson, S. A., Papi, A. A., Singh, D., Laws, E., Dakin, P., et al. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107846 · Cited by 14
Wang, C., Lee, Y., Lin, Y.-P., Chung, W.-H., Tzeng, Y., & Lee, C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.06.036 · Cited by 12
Sernicola, A., Gattazzo, I., Staso, F. D., Giordano, D., Capalbo, A., Persechino, F., Scuderi, G., & Persechino, S. (2019) · Dermatologic Therapy · doi:10.1111/dth.13134 · Cited by 12
Zhou, P., Zheng, T., Li, Y., Zhang, X., Feng, J., Wei, Y., Wang, H., Yao, Y., Gong, F., Tian, W., et al. (2020) · Environmental Science & Technology · doi:10.1021/acs.est.0c03758 · Cited by 12
Effect of inactivated nature‐derived microbial composition on mouse immune system
González‐Rodríguez, M. I., Nurminen, N., Kummola, L., Laitinen, O. H., Oikarinen, S., Parajuli, A., Salomaa, T., Mäkelä, I., Roslund, M. I., Sinkkonen, A., et al. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.579 · Cited by 13
Maspero, J. F., Cardona, G., Schonffeldt, P., Tolcachier, A., Díaz, S. N. G., Yáñez, A., Galvão, C. E. S., Msihid, J., Gall, R., Siddiqui, S. S., et al. (2022) · Journal of Asthma · doi:10.1080/02770903.2022.2115927 · Cited by 12
Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment
Shih, P., Li, C.-J., & Yong, S. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111029 · Cited by 14
Biologic therapies for severe asthma with persistent type 2 inflammation
Chandrasekara, S. D., & Wark, P. A. B. (2024) · Australian Prescriber · doi:10.18773/austprescr.2024.015 · Cited by 12
Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
Xu, X., Zheng, Y., Zhang, X., He, Y., & Li, C. (2017) · Oncotarget · doi:10.18632/oncotarget.22499 · Cited by 13
Targetable pathogenic mechanisms in nasal polyposis
Schneider, A. L., Schleimer, R. P., & Tan, B. K. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22787 · Cited by 12
Unlocking STING as a Therapeutic Antiviral Strategy
Paulis, A., & Tramontano, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087448 · Cited by 12
Drugmakers cling to dual IL-13/IL-4 blockbuster hopes
Sheridan, C. (2018) · Nature Biotechnology · doi:10.1038/nbt0118-3 · Cited by 12
Huang, W., Liou, C., Shen, S., Hu, S., Chao, J. C.-J., Huang, C., & Wu, S. (2022) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200122-1309 · Cited by 12
Redhu, D., Francuzik, W., Globig, P., & Worm, M. (2025) · Clinical and Translational Allergy · doi:10.1002/clt2.70062 · Cited by 11
Distinct subsets of innate lymphoid cells in nasal polyp
Kim, D. H., Lim, J. Y., Jang, J. Y., Gwak, J. W., Joo, H. A., Ryu, S. S., & Kim, J. H. (2022) · Allergology International · doi:10.1016/j.alit.2022.06.007 · Cited by 11
Immunotherapy in Atopic Dermatitis
Li, W., & Man, X. (2022) · Immunotherapy · doi:10.2217/imt-2022-0054 · Cited by 12
Li, M., Zhong, X., & Xu, W. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.11.003 · Cited by 11
The Relationship Between Asthma and Food Allergies in Children
Cunico, D., Giannì, G., Scavone, S., Buono, E. V., & Caffarelli, C. (2024) · Children · doi:10.3390/children11111295 · Cited by 15
van der Schaft, J., Thijs, J. L., de Bruin-Weller, M. S., & Balak, D. (2019) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000551 · Cited by 13
Pharmacokinetics and Concentration‐Response of Dupilumab in Patients With Seasonal Allergic Rhinitis
Kamal, M. A., Franchetti, Y., Lai, C., Xu, C. R., Wang, C. Q. F., Radin, A. R., O’Brien, M. P., Ruddy, M. K., & Davis, J. D. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2004 · Cited by 13
Eichenfield, L. F., Armstrong, A. W., Guttman‐Yassky, E., Lio, P., Chen, C., Hines, D. M., McGuiness, C. B., Ganguli, S., Delevry, D., Sierka, D., et al. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00731-z · Cited by 12
Sico, I. P., Oberle, A. J., Thomas, S. M., Barsanti, T., Egbuonu‐Davis, L., Kennedy, D. T., Zullig, L. L., & Bosworth, H. B. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s303841 · Cited by 11
Andrzejczak, K., Sternak, A., Witkowski, W., & Ponikowska, M. (2025) · Cells · doi:10.3390/cells14181442 · Cited by 10
“This disease is characterised by a predominant immune response driven by activation of the Th2 inflammatory axis, making blockade of the key cytokines in this pathway an effective therapeutic approach [7,112,113].”
de la Fuente, E. G., Alobid, I., Ojanguren, Í., Rodríguez‐Vázquez, V., Pais, B., Reyes, V., Espinosa, M., Smith, Á. L. D. T., Muerza, I., & Vidal-Barraquer, E. (2023) · Frontiers in Allergy · doi:10.3389/falgy.2023.1296894 · Cited by 11
Lung Immune Cell Niches and the Discovery of New Cell Subtypes
Shan, Q., Qiu, J., Dong, Z., Xu, X., Zhang, S., Ma, J., & Liu, S. (2024) · Advanced Science · doi:10.1002/advs.202405490 · Cited by 15
Tian, M., Huang, W., Chen, J., Liu, X., Wang, H., Pan, X., Wang, L., Li, Q., Gao, L., & Ye, Y. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119038 · Cited by 10
Sun, Y.-G., & Zhang, L.-Y. (2025) · Allergy medicine. · doi:10.1016/j.allmed.2025.100036 · Cited by 10
The management of type 2 inflammatory respiratory diseases: a Chinese expert consensus [2024]
on behalf of Respiratory Allergy Disease Group, T. C. A. S., Jia, N., Jin, M., Liu, Y., Su, N., Sun, Y., Tang, W., Wang, G., Xie, H., Xie, J., et al. (2025) · Journal of Thoracic Disease · doi:10.21037/jtd-2024-2092 · Cited by 13
Wei, H., Chen, Z., Lai, W., Wang, W., Bian, X., Zhang, L., & Li, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1591394 · Cited by 10
Silverberg, J. I., Simpson, E. L., Guttman‐Yassky, E., Cork, M. J., de Bruin-Weller, M. S., Yosipovitch, G., Eckert, L., Chen, Z., Ardeleanu, M., Shumel, B. S., et al. (2020) · Dermatitis · doi:10.1097/der.0000000000000698 · Cited by 11
Self-citationKang, J., Lee, S., Kim, N.-K., Dhakal, H., Kwon, T., Kim, E., Jeong, G., & Kim, S. (2021) · Molecules · doi:10.3390/molecules26154409 · Cited by 10
Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities
Boguniewicz, M., Sher, L., Paller, A. S., Arkwright, P. D., Yoshihara, S., Chen, Z., Shah, P., & Marco, A. R. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02998-4 · Cited by 10
Kosoy, I., Lew, E., Ledanois, O., & Derrickson, W. (2021) · Journal of Asthma · doi:10.1080/02770903.2021.1895208 · Cited by 10
Guimarães, C. C., Sandy, C. M., Figueira, R. L., GONÇALVES, M. D. R., Crevelin, E. J., Cardoso, P. H., Fabro, A. T., Carmona, F., Borges, M. D. C., & Pereira, A. M. S. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115877 · Cited by 10
Liu, Z., Al-Quran, L., Tong, J., & Cao, X. (2023) · Archives of Dermatological Research · doi:10.1007/s00403-023-02564-y · Cited by 12
Effects of dupilumab in type 1 neurofibromatosis coexisting with severe atopic dermatitis
Chello, C., Sernicola, A., Paolino, G., & Grieco, T. (2021) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2020.10.006 · Cited by 10
Biological Therapies for Asthma
Couillard, S., & Pavord, I. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00071-8 · Cited by 11
Chen, T., Ma, S., Ou, W.-F., Chen, C.-C., & Wu, C.-Y. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2025.08.020 · Cited by 9
Metadata
- Authors
- Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D.
- Affiliations
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- Corresponding author
- Gandhi, Namita A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-10-16
- Volume
- 15
- Issue
- 1
- Pages
- 35-50
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2200308911
- Cited by
- 766
- References
- 156
- Citations by year
- 2026: 70 · 2025: 104 · 2024: 113 · 2023: 77 · 2022: 106 · 2021: 99 · 2020: 63 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 18
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Keywords
- type 2 inflammation, IL-4, IL-5, IL-13, asthma, atopic dermatitis, Th2 cells, allergic diseases, IL-4 receptor alpha inhibition, IL-13 inhibition, IL-5 inhibition, personalized asthma therapy, drug candidates
- MeSH terms
- Antibodies, Monoclonal, T-Lymphocytes, Helper-Inducer, Humans, Inflammation, Interleukin-4, Interleukin-5, Models, Immunological, Interleukin-13, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.